ADGRL4
Adhesion G protein-coupled receptor L4
Also known as: AGRL4_HUMAN, ELTD1, ETL
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9HBW9
- Gene
- ADGRL4
- Ensembl
- ENSG00000162618
- Chromosome
- 1
- Canonical length
- 690 aa
- Protein class
- G-protein coupled receptors, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters
OverviewNCBI Gene
Predicted to enable G protein-coupled receptor activity. Predicted to be involved in adenylate cyclase-activating G protein-coupled receptor signaling pathway. Predicted to be located in cytoplasmic vesicle. Predicted to be active in plasma membrane. Biomarker of glioblastoma and hypertrophic cardiomyopathy. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
690 residues, UniProt reviewed canonical sequence.
>Q9HBW9|ADGRL4
1 MKRLPLLVVF STLLNCSYTQ NCTKTPCLPN AKCEIRNGIE ACYCNMGFSG NGVTICEDDN
61 ECGNLTQSCG ENANCTNTEG SYYCMCVPGF RSSSNQDRFI TNDGTVCIEN VNANCHLDNV
121 CIAANINKTL TKIRSIKEPV ALLQEVYRNS VTDLSPTDII TYIEILAESS SLLGYKNNTI
181 SAKDTLSNST LTEFVKTVNN FVQRDTFVVW DKLSVNHRRT HLTKLMHTVE QATLRISQSF
241 QKTTEFDTNS TDIALKVFFF DSYNMKHIHP HMNMDGDYIN IFPKRKAAYD SNGNVAVAFV
301 YYKSIGPLLS SSDNFLLKPQ NYDNSEEEER VISSVISVSM SSNPPTLYEL EKITFTLSHR
361 KVTDRYRSLC AFWNYSPDTM NGSWSSEGCE LTYSNETHTS CRCNHLTHFA ILMSSGPSIG
421 IKDYNILTRI TQLGIIISLI CLAICIFTFW FFSEIQSTRT TIHKNLCCSL FLAELVFLVG
481 INTNTNKLFC SIIAGLLHYF FLAAFAWMCI EGIHLYLIVV GVIYNKGFLH KNFYIFGYLS
541 PAVVVGFSAA LGYRYYGTTK VCWLSTENNF IWSFIGPACL IILVNLLAFG VIIYKVFRHT
601 AGLKPEVSCF ENIRSCARGA LALLFLLGTT WIFGVLHVVH ASVVTAYLFT VSNAFQGMFI
661 FLFLCVLSRK IQEEYYRLFK NVPCCFGCLRLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ADGRL4 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 7
- Mean surface accessibility (rSASA)
- 0.3
- Highest tissue expression
- 64 nTPM
Expression across tissuesHPA
Tissue
- adipose tissue: 64 nTPM
- breast: 57 nTPM
- spleen: 38 nTPM
- smooth muscle: 26 nTPM
- urinary bladder: 22 nTPM
- tongue: 22 nTPM
Single-cell type
- vascular endothelial cells: 743 nCPM
- lymphatic endothelial cells: 146 nCPM
- late spermatids: 111 nCPM
- late primary spermatocytes: 88 nCPM
- early spermatids: 52 nCPM
- fibro-adipogenic progenitors: 34 nCPM
Immune cell
- neutrophil: 0.1 nTPM
- T-reg: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
Brain region
- thalamus: 13 nTPM
- pons: 12 nTPM
- cerebral cortex: 11 nTPM
- medulla oblongata: 11 nTPM
- white matter: 9.9 nTPM
- cerebellum: 9.1 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1
- gnomAD pLI
- 0
- DepMap mean gene effect
- 0.14
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- EGF-type aspartate/asparagine hydroxylation site
- GPS motif
- EGF-like domain
- GPCR, family 2, secretin-like
- EGF-like calcium-binding domain
- GPCR, family 2-like, 7TM
- GPCR, family 2, secretin-like, conserved site
- EGF-like calcium-binding, conserved site
- AGRL2-4 , GAIN subdomain A
- GAIN domain superfamily
- NOTCH1, EGF-like calcium-binding domain
- GAIN, subdomain B
- 7 transmembrane receptor (Secretin family)
- GPCR proteolysis site, GPS, motif
- Calcium-binding EGF domain
- AGRL2-4 GAIN subdomain A
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ADGRL4 as an antibody target. Whether an autoantibody or antibody against ADGRL4 could matter depends on whether native ADGRL4 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ADGRL4 is annotated at the cell surface, where native ADGRL4 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label ADGRL4 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...